Clinical trial NCT00413192: E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
Official title: Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Soft Tissue Sarcoma
Lead sponsor: Eisai Inc.
Sponsor class: INDUSTRY
First posted: 2006-12-19
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the therapeutic activity and safety of E7389 in patients with advanced/metastatic soft tissue sarcoma who have failed standard chemotherapy.


Eligibility criteria: Inclusion Criteria:

1. Histologically proven advanced and/or metastatic malignant soft tissue sarcoma of high or intermediate grade, and of one of the following histologies (World Health Organization (WHO) classification 2002):

   * Leiomyosarcoma
   * Adipocytic (liposarcoma dedifferentiated, myxoid/round cell, pleomorphic, mixed-type not otherwise specified)
   * Synovial sarcoma
   * Other types of sarcoma, including:
   * Fibroblastic (adult fibrosarcoma, myxofibrosarcoma, sclerosing epithelioid fibrosarcoma).
   * So-called fibrohistiocytic (pleomorphic Malignant Fibrous Histiocytoma (MFH), giant cell "MFH", inflammatory "MFH")
   * Malignant glomus tumors.
   * Skeletal muscles (rhabdomyosarcoma, alveolar or pleomorphic) excluding embryonal rhabdomyosarcoma.
   * Vascular (epithelioid haemangioendothelioma, angiosarcoma).
   * Uncertain differentiation (synovial, epithelioid, alveolar soft part, clear cell, desmoplastic small round cell, extra-renal rhabdoid, malignant mesenchymoma, perivascular epithelioid cell tumor (PEComa), intimal sarcoma) excluding chondrosarcoma, Ewing tumors / Primitive neuroectodermal tumor (PNET)
   * Malignant peripheral nerve sheath tumors.
   * Malignant solitary fibrous tumors.
   * Undifferentiated soft tissue sarcomas not otherwise specified.
   * Other types of sarcoma (not listed as not eligible), if approved by the Study Coordinator (written or e-mail approval needed prior to registration).
   * The following tumor types are not eligible:
   * Embryonal rhabdomyosarcoma
   * Chondrosarcoma
   * Osteosarcoma
   * Ewing tumors / PNET
   * Gastro-intestinal stromal tumors (GIST)
   * Dermatofibrosarcoma protuberans
   * Inflammatory myofibroblastic sarcoma
   * Neuroblastoma
   * Malignant mesothelioma
   * Mixed mesodermal tumors of the uterus
2. Formalin fixed paraffin embedded tumor blocks and representative H/E (hematoxylin/eosin) slides must be available for histological central review. Histological central review is not required before treatment start but is mandatory within 10 days of registration. Local histopathological diagnosis will be accepted for entry into the study.
3. Relapsed, refractory and/or metastatic disease incurable by surgery or radiotherapy.
4. Evidence of objective progression within the last 6 months (RECIST) documented by measurements of disease, i.e. appearance of new lesions, increase of 20% in the sum of the diameters of measurable lesions, or progression of non measurable lesions to be confirmed by an external review, without other specific treatment since objective documentation of progression.
5. Presence of measurable disease, as defined by RECIST.
6. Patients must have received no more than one combination or two single agent chemotherapy regimens for advanced disease; (neo)adjuvant therapy is not counted towards this requirement.
7. No major surgery, hormonal therapy (other than replacement), chemotherapy or radiotherapy, immunotherapy or other investigational agent within the last 28 days and/or not recovered from prior therapy within the last 28 days. Use of erythropoietin is considered supportive care and is permitted.
8. Absence of brain or subdural metastases, unless patient has completed local therapy and has discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment with E7389. Any signs (e.g., radiologic) and/or symptoms of brain metastases must be stable for at least 4 weeks.
9. Absence of pre-existing neuropathy \> Grade 2
10. At least 18 years of age.
11. WHO performance status 0 or 1.
12. Adequate bone marrow function (absolute neutrophil count \>1.5 x 109/L, platelets \>100 x 109/L)
13. Adequate hepatic function (bilirubin \< 1.5 mg/mL or 25 µmol/L, SGOT/AST and SGPT/ALT \<= 3 x UNL or \< 5 x UNL in patients with liver metastases).
14. Adequate renal function: serum creatinine \< 2.0 mg/dl or 177 µmol/l or calculated (Cockcroft and Gault formula) creatinine clearance \> 40 ml/min.
15. Women should either not be of childbearing potential (having had a hysterectomy, a bilateral oophorectomy or bilateral tubal ligation, or be post-menopausal with a total cessation of menses of \>1 year), or not be pregnant (negative serum pregnancy test at entry), should not be lactating, should agree to use contraceptive methods (with a documented failure rate \< 1%, vasectomized partner sterile prior to trial entry and sole sexual partner or double-barrier contraception) while on treatment and during a period of 3 months after the end of treatment. Sexually active male participants must use barrier methods of contraception.
16. Before patient registration/randomization, written informed consent must be given according to International Conference on Harmonization/Good Clinical Practice (ICH/GCP), and national/local regulations.

Exclusion Criteria:

1. Prior history of malignancies other than sarcoma (except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or the patient has been free of any other malignancies for \> 3 years).
2. Significant cardiovascular impairment (history of congestive heart failure \> New York Heart Association (NYHA) grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).
3. Patients who are receiving anti-coagulant therapy with warfarin or related compounds, other than for line patency, and cannot be changed to heparin-based therapy, are not eligible. If a patient is to continue on mini-dose warfarin, then the prothrombin time (PT) / international normalized ratio (INR) must be closely monitored.
4. Severe/uncontrolled intercurrent illness/infection.
5. Patients with a known hypersensitivity to halichondrin B and/or halichondrin B chemical derivative.
6. Patients who participated in a prior E7389 clinical trial.
7. Patients without freedom (by the law or administrative decision), hospitalized without their consent (mental disability, upon legal request), admitted in medical or social establishment for other reasons than clinical research, with any psychological, familial, sociological, geographical condition potentially hampering compliance with the study protocol and follow-up schedule ; those conditions should be assessed with the patient before registration in the trial.

Primary outcomes:
measure: Progression Free Survival (PFS) at 12 Weeks
timeFrame: Week 12
Secondary outcomes:
measure: Overall Progression Free Survival
timeFrame: First dose of study drug to the date of disease progression or date of death, whichever occurs first, or date of study cut-off 28 Jun 2012, up to 5.5 years
measure: Objective Response Rate (ORR)
timeFrame: Date of first dose of study drug until documentation of CR or PR, or up to data cutoff 28 Jun 2012, up to approximately 5.5 years
measure: Clinical Response Benefit (CRB)
timeFrame: Date of first dose of study drug to documentation of CR, PR, or SD, or until data cutoff date 28 Jun 2012, up to approximately 5.5 years
measure: Time to Onset of Response
timeFrame: Date of first dose of study drug to date of first documented CR or PR, or until data cutoff date 28 Jun 2012, up to approximately 5.5 years
measure: Duration of Response
timeFrame: Date of first documented CR or PR until the date of first document disease progression (or death), or up to data cutoff 28 Jun 2012, up to approximately 5.5 years
measure: Overall Survival (OS)
timeFrame: Date of first dose of study drug to date of death from any cause, or up to cut-off date of 28 Jun 2012, up to approximately 5.5 years
measure: Summary of Adverse Events (AEs)
timeFrame: Day 1 of study treatment until progressive disease, or up to cut-off date of 28 Jun 2012, up to approximately 5.5 years
Other outcomes:
Locations:
city: Brussels
country: Belgium
city: Leuven
country: Belgium
city: Aarhus
country: Denmark
city: Herlev
country: Denmark
city: Bordeaux
country: France
city: Lyon
country: France
city: Marseille
country: France
city: Villejuif
country: France
city: Bad Saarow
country: Germany
city: Dresden
country: Germany
city: Essen
country: Germany
city: Hannover
country: Germany
city: Mannheim
country: Germany
city: Tuebingen
country: Germany
city: Warsaw
country: Poland
Study officials:
References:
citation: Wiemer EAC, Wozniak A, Burger H, Smid M, Floris G, Nzokirantevye A, Sciot R, Sleijfer S, Schoffski P. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. Eur J Cancer. 2017 Apr;75:33-40. doi: 10.1016/j.ejca.2016.12.018. Epub 2017 Feb 16.
citation: Schoffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grunwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P; European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011 Oct;12(11):1045-52. doi: 10.1016/S1470-2045(11)70230-3. Epub 2011 Sep 19.